Indonesian Minister of Health, Budi G. Sadikin carried out the groundbreaking of the construction of PT Triman's fractionated plasma facility in Jababeka Industrial Estate, Cikarang, Bekasi, West Java, on Tuesday (05/12/2023).

The construction of the fractionation plant is a collaboration between the Ministry of Health and the Indonesian Red Cross, PT Triman - Green Cross Biopharma Corp and PT Medquest Mitra Indonesia.

Minister of Health of the Republic of Indonesia, Budi Gunadi Sadikin in his speech said that the Groundbreaking of PT Triman's Plasma Fractionation Facility was carried out, referring to the Decree of the Minister of Health of the Republic of Indonesia Number. HK.01.07/MENKES/1349/2023, which has determined PT Triman - GC Biopharmas Corp as a Plasma Fractionation Facility.

The Minister of Health hopes that the existence of the first plasma fractionation plant in Indonesia will fulfill the need for plasma products in Indonesia. "Currently, the need for plasma fractionation continues to increase, both at the global and national levels," he said.

"The government will strengthen in terms of policies and facilitate the supply of raw materials, standardize raw materials, and provide guidance to plasma suppliers so that there are more of them," said the Minister of Health.

Plasma Fractionation is the separation of plasma derivatives into plasma products by applying technology in blood processing. Plasma products or also known as Plasma Derivate Drug Products (PDOB) are finished preparations resulting from plasma fractionation that have medicinal properties.

Plasma Derivat Medicinal Products include first, Albumin which treats or prevents shock in individuals with severe injuries, bleeding, surgery or burns.

In addition, albumin supports tissue growth and repair, and assists in fluid removal during dialysis.

Second, Immunoglobulin is used for the treatment of various immunodeficiency conditions and a number of other conditions related to weakened body defenses such as autoimmune, infectious, and inflammatory conditions.

Third, factor VIII is for the treatment of hemophilia, supporting normal blood clot formation and preventing excessive bleeding.

Plasma derivate products are widely used by the pharmaceutical industry for chronic disease therapy and treatment of critical patients. Unfortunately, until now Indonesia is still dependent on imported products in meeting the needs of these plasma derivative drugs.

Chairman of the Indonesian Red Cross (PMI) Jusuf Kalla highly appreciates the Indonesian government's move to realize the construction of plasma fractionation in Indonesia. "The plan to build this plant has actually been initiated since 15 years ago but can only be realized this year," he said. "I hope that the plasma fractionation facility can be implemented optimally by involving many parties, so that the target to meet the need for 400 thousand liters of blood plasma by 2025 can be achieved," concluded Jusuf Kalla.